abstract |
The present invention provides an antibody that binds to human OX40 (ACT35, CD134 or TNFRSF4) and an antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody, and the use of the antibody or composition for treating diseases such as cancer. In particular, the anti-OX40 antibody of the present invention does not interfere with the binding of the OX40-ligand to its receptor. |